help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DAVIES, C. W. H.
Right arrow Articles by DAVIES, R. J. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DAVIES, C. W. H.
Right arrow Articles by DAVIES, R. J. O.

Am. J. Respir. Crit. Care Med., Vol 157, No. 1, 01 1998, 328-330.

The systemic fibrinolytic activity of intrapleural streptokinase [In Process Citation]

CW Davies, S Lok and RJ Davies
Osler Chest Unit, Churchill Hospital, Headington, Oxford, United Kingdom.

Intrapleural fibrinolytics probably improve the drainage of loculated pleural effusions and empyemas. Studies of crude indices of systemic coagulation suggest this effect is accompanied by little systemic fibrinolysis, but few studies have assessed this in detail. This study examines the systemic fibrinolytic activity of two intrapleural streptokinase (IPSK) regimes in detail. Eight patients received a single dose of 250,000 IU IPSK, and a further eight received serial doses of 250,000 IU IPSK every 12 h for 3 d (total dose: 1.5 million IU). Each dose was retained in the pleural cavity for 2 h. Venous blood for prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, and D-dimers due to fibrin degradation were measured before any IPSK. These end points were then remeasured 24 h after IPSK in the single-dose group and after 24, 48, and 72 h in the group receiving serial doses. There were no physiologic or statistical differences in any of the indices after administration of IPSK. IPSK administered up to a dose of 1.5 million IU does not cause significant activation systemic fibrinolysis in humans.


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Idell, A. Mazar, D. Cines, A. Kuo, G. Parry, S. Gawlak, J. Juarez, K. Koenig, A. Azghani, W. Hadden, et al.
Single-Chain Urokinase Alone or Complexed to Its Receptor in Tetracycline-induced Pleuritis in Rabbits
Am. J. Respir. Crit. Care Med., October 1, 2002; 166(7): 920 - 926.
[Abstract] [Full Text]

Home page
 ThoraxHome page
A H Thomson, J Hull, M R Kumar, C Wallis, and I M Balfour Lynn
Randomised trial of intrapleural urokinase in the treatment of childhood empyema
Thorax, April 1, 2002; 57(4): 343 - 347.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. W. H. Davies, Z. C. Traill, F. V. Gleeson, and R. J. O. Davies
Intrapleural Streptokinase in the Management of Malignant Multiloculated Pleural Effusions
Chest, March 1, 1999; 115(3): 729 - 733.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1998 American Thoracic Society 		  ATS State of the Art 2009